Ebola’s Spread Sparks Debate on Developmental Medicines

Global Security Newswire Staff
Add to Briefcase
Global Security Newswire Staff
July 10, 2014, 9:29 a.m.

Spe­cial­ists are de­bat­ing calls to em­ploy de­vel­op­ment­al medi­cines against an Ebola out­break ravaging West Africa, the Ca­na­dian Press re­ports.

A num­ber of ana­lysts said dis­trib­ut­ing vac­cines or drug treat­ments that are not fully tested may boost loc­al dis­trust of of­fi­cials that have been fight­ing the spread of Ebola hem­or­rhagic fever since March, the news agency re­por­ted on Wed­nes­day. No fully vet­ted medi­cines cur­rently ex­ist for the dis­ease, which as of Tues­day may have killed more than 500 people in Guinea, Liber­ia and Si­erra Le­one.

Ac­cord­ing to some op­pon­ents of us­ing such medi­cines, any ad­verse side ef­fects may threaten years of ef­forts to de­vel­op the drugs as a de­fense against the po­ten­tial bio­lo­gic­al-weapon agent.

“It would be un­eth­ic­al to roll [de­vel­op­ment­al medi­cines] out now, in my opin­ion,” said Dav­id Hey­mann, a former World Health Or­gan­iz­a­tion as­sist­ant dir­ect­or gen­er­al.

Of­fi­cials could in­stead move, once the cur­rent threat sub­sides, to lay the ground­work for us­ing such treat­ments to com­bat fu­ture out­breaks, Hey­mann ar­gued. The World Health Or­gan­iz­a­tion could make such policy pre­par­a­tions in col­lab­or­a­tion with drug de­velopers and re­gion­al gov­ern­ments, he said.

One ex­pert, though, pressed for im­me­di­ately us­ing Ebola coun­ter­meas­ures now in a late stage of de­vel­op­ment.

“Ima­gine if you take a re­gion of Canada, Amer­ica, Europe and you had 450 people dy­ing of a vir­al hem­or­rhagic fever. It would just be un­ac­cept­able — and it’s un­ac­cept­able in West Africa,” said Jeremy Far­rar, a trop­ic­al medi­cine and glob­al health spe­cial­ist at Ox­ford Uni­versity.

What We're Following See More »
TRUMP TOWER MEETING
Statehood, Metro Come Up as Bowser Meets Trump
2 minutes ago
THE LATEST

DC Mayor Muriel Bowser met with Donald Trump this morning in Manhattan, with statehood and the Metro system on the agenda. “We talked about the things that are important to Washingtonians, and certainly becoming the 51st state is one of them," she said after the meeting. She also made the point that the District is “not dependent on the federal government for our funds," and brought up funding for Metro. She told reporters that Trump is a fan of D.C.

Source:
EVENT IN NC
Mattis Gets the Official Nod Tonight
1 hours ago
WHY WE CARE
LOWER COURT TO DETERMINE NEW DAMAGES
SCOTUS Sides with Samsung Over Apple
1 hours ago
THE LATEST

"A unanimous Supreme Court on Tuesday sided with smartphone maker Samsung in its high-profile patent dispute with Apple over design of the iPhone. The justices said Samsung may not be required to pay all the profits it earned from 11 phone models because the features at issue are only a tiny part of the devices. Apple had won a $399 million judgment against Samsung for copying parts of the iPhone's patented design, but the case now returns to a lower court to decide what Samsung must pay."

Source:
AFRAID OF BUDGET CUTS
Pentagon Hid Evidence of Waste
2 hours ago
THE DETAILS

"The Pentagon has buried an internal study that exposed $125 billion in administrative waste in its business operations amid fears Congress would use the findings as an excuse to slash the defense budget, according to interviews and confidential memos obtained by The Washington Post."

Source:
TRUMP IS “NOT QUALIFIED FOR THE OFFICE”
Texas GOP Elector Won’t Cast Vote For Trump
2 hours ago
THE LATEST

Christopher Suprun, a GOP elector from Texas, announced in an op-ed for The New York Times that he will not cast his vote in the electoral college for Donald Trump. This one vote will not keep Trump from getting to the 270 necessary to secure an electoral victory, but stands as a strong statement of rebuke. "I am asked to cast a vote on Dec. 19 for someone who shows daily he is not qualified for the office," Suprun wrote.

Source:
×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login